hsa-miR-6089: Hsa-mir-6089 is a microRNA that has been added to version 19 of the microarray analysis [PMC5648749]. It is one of the four candidate miRNAs selected from plasma samples of CAD patients and healthy controls [PMC6769746]. Hsa-mir-6089, along with other microRNAs, has been found to have differential expression linked to Alzheimer's disease [PMC9312389]. It has also been reported that hsa-mir-6089 can be up-regulated by apigenin, a compound with potential therapeutic effects [PMC8095173]. Hsa-mir-6089 is downregulated in patients with cardiovascular events and has been associated with inflammation and stroke [PMC9827273]. Additionally, hsa-mir-6089 is one of the X-linked miRNAs that show differential expression in certain conditions [PMC5324395]. It plays a crucial role in regulating inflammation through its interaction with TLR4 [PMC7474783]. Hsa-mir-6089 has also been found to downregulate an SNP (rs751012151) in MRPL4, potentially affecting drug resistance [PMC5396474]. Furthermore, hsa-mir-6089 is one of the miRNAs significantly correlated with pancreatic ductal adenocarcinoma (PDAC) diagnosis [PMC8301411]. Validation studies have confirmed its upregulation in PDAC patients compared to controls using qRT-PCR analysis [PMC8301411]. Hsa-mir-6089 is one of the two miRNAs that are ubiquitously expressed across different tissues and have low tissue-specificity index measures [PMC6245813].